Balveen Kaur

Professor and Associate Director

Augusta University

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Balveen Kaur serves as the Associate Director at Augusta University in the United States. Her research primarily focuses on oncolytic virotherapy and cancer immunotherapy, exploring novel therapeutic strategies and drug interactions. Recent publications highlight her work on engineering oncolytic HSV strains and investigating the tumor microenvironment to enhance treatment effectiveness.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (5)

Ji Young Yoo

Assistant Professor

The University of Texas Health Science Center at Houston School of Public Health

UNITED STATES

View details

Yoshihiro Otani

Assistant Professor

Okayama University Hospital

JAPAN

View details

David Munn

Augusta University

UNITED STATES

View details

Bhanu Ganesh

Assistant professor

The University of Texas Health Science Center at Houston

UNITED STATES

View details

Holly Stessman

Assistant Professor

Creighton University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Balveen Kaur

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Oncolytic HSV and cancer drug interactions: Current clinical status and future directions

Cancer interrupted: A story of oncolytic HSV-induced killing

Engineering a novel HSV-1 strain for oncolytic therapy of solid tumors

β-blocker suppresses both tumoral sympathetic neurons and perivascular macrophages during oncolytic herpes virotherapy

Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy.

Exogenous non-coding dsDNA-dependent trans-activation of phagocytes augments anti-tumor immunity.

esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation

PKR induces TGF-β and limits oncolytic immune therapy.

Triple combination therapy for pancreatic cancer remodels stroma and improves survival

oHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy

Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.

The Notch signaling pathway: a potential target for cancer immunotherapy.

Correction: Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus.

Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus

Histone modifiers at the crossroads of oncolytic and oncogenic viruses

Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer

An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma

Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity

ATF3 Coordinates Antitumor Synergy between Epigenetic Drugs and Protein Disulfide Isomerase Inhibitors

Glioma induced alterations in fecal short-chain fatty acids and neurotransmitters

Collaborators (5)

Ji Young Yoo

Yoshihiro Otani

David Munn

Bhanu Ganesh

Holly Stessman

Make your next move.